On May 21, 2024, the Company announced that the U.S. Food and Drug Administration (FDA) provided clearance for the Company’s investigational new drug (IND) application to proceed with a Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback